Niraparib in pancreatic cancer with germline or somatic DNA damage repair (DDR) gene alterations (BRCA and beyond): A phase II study (NIRA-PANC) - PubMed
3 hours ago
- #pancreatic cancer
- #PARP inhibitor
- #DNA damage repair
- Phase II study evaluated niraparib in advanced pancreatic cancer with DNA damage repair (DDR) gene alterations.
- Primary endpoint: 6-month progression-free survival (PFS) rate was 41.38% in 29 efficacy-evaluable patients.
- Median PFS was 4.4 months and median overall survival (OS) was 10.3 months across the cohort.
- Subgroup analysis showed better outcomes in BRCA1/2 germline mutation patients (50% 6-month PFS, 12.1 months median OS) compared to non-BRCA group.
- Adverse events occurred in 78% of patients, with anemia being most common; no treatment-related deaths reported.
- Results indicate clinical activity of niraparib in this patient population, warranting further research in diverse genetic subgroups.